Curiox Partners with Professor Marco Ruella, Who Led the World's First Commercialized CAR-T Therapy

Curiox, which will be listed on KOSDAQ on the 10th of next month, is conducting joint research with the research team that led the world's first commercialization of CAR-T cell therapy.

Curiox Biosystems (hereinafter Curiox, CEO Namyong Kim), a leading company in cell analysis process automation, officially announced on the 28th that it has signed a joint research agreement with Prof. Marco Ruella MD of the University of Pennsylvania School of Medicine.

Under this partnership, Curiox will support the development of next-generation cancer cell therapies at the Hematologic Malignancies Innovation Center of the University of Pennsylvania School of Medicine by providing its accurate and highly reproducible cell analysis process automation platform, the Lamina Wash™ equipment and technology. The Hematologic Malignancies Innovation Center at the University of Pennsylvania School of Medicine has been focusing on cutting-edge research related to chronic lymphocytic leukemia (CLL) and lymphoma research and treatment.

Curiox stated, "Professor Marco Ruella is a top global authority in the field who succeeded in the world's first commercialization of CAR-T therapy and boasts overwhelming experience in the development of innovative cell therapies." They added, "Curiox will combine its next-generation cell analysis process platform with Professor Ruella's expertise in Cell and Gene Therapies (CGT) to advance cell analysis technology that leads the CGT industry." In fact, Curiox's Lamina Wash utilizes laminar flow-based microfluidic technology to minimize cell loss and deformation, demonstrating consistent research reproducibility without researcher bias, making it increasingly demanded as an essential standard operating procedure (SOP) in the CGT industry's cell analysis processes.

Regarding this, Curiox CEO Namyong Kim said, "We are very pleased to establish a Center of Excellence (COE) for automated cell analysis processes together with Professor Ruella." He added, "We aim to automate and accurately perform the analysis stage, a critical step in cell therapy development and manufacturing processes, to accelerate the development of existing cell therapies and further create an excellent model where laboratory research results lead to positive outcomes in practical clinical applications."

Meanwhile, Curiox is conducting demand forecasting on the 27th and 28th with Kiwoom Securities as the lead underwriter, followed by subscription on August 1st and 2nd, and is scheduled to be listed on August 10th.

This content was produced with the assistance of AI translation services.